Synergy Pharmaceuticals to Present at Two Upcoming Investment Conferences

NEW YORK--(BUSINESS WIRE)--

Synergy Pharmaceuticals Inc. SGYP, today announced its Chairman and Chief Executive Officer, Dr. Gary S. Jacob, will present a corporate update at two February investment conferences being held at the Waldorf Astoria in New York, N.Y.

Synergy is scheduled to present at the BIO CEO & Investor Conference on Tuesday, February 10^th at 8:30am (EST), and at the Leerink Global Healthcare Conference on Thursday, February 12^th at 1:25pm (EST).

A live webcast of both presentations will be accessible through the Investors section of the company's website at www.synergypharma.com. To access the webcast, please log on to the Synergy website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Synergy's website for approximately 180 days following the conference.

About Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals SGYP is a biopharmaceutical company focused on the development of novel therapies to treat gastrointestinal (GI) diseases and disorders. The company's proprietary platform technology is based on the naturally occurring human GI hormone – uroguanylin - a key regulator of normal GI physiology. Synergy has created two unique analogs of uroguanylin - plecanatide and SP-333 – both designed to mimic the hormone's natural activity and target a variety of GI conditions. Plecanatide is currently in phase 3 clinical development for chronic idiopathic constipation and irritable bowel syndrome with constipation. SP-333 has successfully completed a phase 2 study in patients with opioid-induced constipation and is presently being evaluated for the treatment of ulcerative colitis. For more information, please visit www.synergypharma.com.